| Osteosarcoma is the most common type of bone cancer, and it generally affects young people under the age of 25. Twenty years ago, the standard treatment was amputation of the affected limb, and the 5-year survival rate was less than 20 percent. Today, modular replacements and advances in chemotherapy and radiation have revolutionized treatment, allowing most patients to be treated with limb-sparing surgery—resulting in a 5-year survival rate approaching 80 percent. Stryker’s rotating hinge knee implant components help patients resume active lives because they are modeled after the natural knee joint. |
 |
|
|
| Resection of the distal femur |
| Treating an osteosarcoma requires removing bone with the tumor and replacing the bone with a prosthesis. |
|
Distal femur with
osteosarcoma |
|
| GMRS |
| Stryker’s Global Modular Replacement System replaces bone on a modular, as-needed basis in the hip, femur, knee and tibia. |
|
|
| Cement and mixing equipment |
|
When cement is required in a GMRS procedure, Stryker offers Simplex, the bone cement with the world’s longest clinical history.
Simplex™ P with Tobramycin Bone Cement is indicated for the fixation of prostheses to living bone in the second stage of a two-stage revision for total joint arthroplasty.
|
|
|
| In the operating room |
| Stryker’s heavy duty power tools and personal protection systems for surgical staff enhance the efficiency and safety of the operating room. |
|
|
| Outcome |
| Stryker’s GMRS offers an advanced, flexible modular system to surgeons who face complex cases involving extreme bone loss due to cancer, trauma or the need for complex revision surgery. |
|
Resected distal
femur with GMRS |
|
Revolution cement
System 6 Powered Instruments
T5 Personal Protection System